MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2022 International Congress

    Effect of freezing of gait and antiparkinsonian medication on joint kinematics and kinetics in gait in patients with Parkinson’s disease

    T. Shida, D. Campos, C. Oliveira, R. Treza, S. Hondo, E. Los Angeles, C. Bernardo, L. Oliveira, M. Carvalho, D. Coelho (São Bernardo Campo, Brazil)

    Objective: This study aims to evaluate the interaction between FoG and antiparkinsonian medication on individuals with PD's kinematic and kinetic gait parameters. Background: Regarding Parkinson's…
  • 2022 International Congress

    DIFFERENT PATTERNS OF ACUTE SACCADIC RESPONSES TO LEVODOPA CHALLENGE TEST IN DE NOVO PARKINSON’S DISEASE: POSSIBILE PROGNOSTIC IMPLICATIONS

    C. Terravecchia, G. Mostile, CG. Chisari, A. Luca, R. Terranova, G. Donzuso, CE. Cicero, G. Sciacca, A. Nicoletti, M. Zappia (Catania, Italy)

    Objective: To explore possible different patterns of acute saccadic responses to Levodopa Challenge Test (LCT) in a de novo drug-naïve Parkinson’s Disease (PD) population and…
  • 2022 International Congress

    LFP beta frequency OFF-ON shift in subthalamic nucleus in Parkinson’s disease

    K. Sayfulina, V. Filyushkina, A. Gamaleya, E. Belova, A. Tomskiy, A. Sedov (Moscow, Russian Federation)

    Objective: The aim of the current study is to investigate the frequency characteristics of beta activity in Parkinson’s disease. We hypothesized that beta peak central…
  • 2022 International Congress

    Subcutaneous Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Results From a Randomized, Double-blind, Double-dummy Phase 3 Trial

    M. Soileau, M. Spindler, J. Aldred, K. Budur, N. Fisseha, V. Fung, A. Jeong, T. Kimber, K. Klos, I. Litvan, D. O’Neill, W. Robieson, D. Standaert, S. Talapala, E. Okeanis Vaou, H. Zheng, M. Facheris, R. Hauser (Georgetown, USA)

    Objective: To evaluate the efficacy and safety/tolerability of 24-hour/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (a soluble formulation of levodopa/carbidopa prodrugs) vs oral levodopa/carbidopa in…
  • 2022 International Congress

    Acute polyneuropathy in patients with Parkinson’s disease treated with LCIG

    P. Havránková, R. Jech, M. Baláž, V. čapek, K. Gmitterová, M. Grófik, V. Haň, M. Kaiserová, P. Kaňovský, J. Klempíř, E. Kurča, M. Minár, J. Necpál, I. Rektorová, J. Roth, E. Růžička, M. škorvánek, P. Valkovič (Praha 2, Czech Republic)

    Objective: The aim of the study was to determine whether the daily dose of levodopa equivalent daily dose (LEDD) before and after starting levodopa/carbidopa intestinal…
  • 2022 International Congress

    Reported Clinical and Quality-of-Life Outcomes With 24-Hour Levodopa-Carbidopa Intestinal Gel Administration Compared With 16-Hour Administration

    N. Kovács, M. Simu, O. Sanchez Soliño, J. Parra, J. Alcazar, S. Snedecor, V. Fung (Pécs, Hungary)

    Objective: To evaluate any existing differences between the reported outcomes in patients with advanced Parkinson’s disease (APD) using continuous 16-hour (hr) infusions of levodopa-carbidopa intestinal…
  • 2022 International Congress

    The results of DBS in patients with Parkinson’s disease for 10 years in Belarus

    A. Buniak, V. Alexeyevets, S. Likhachev (Minsk, Belarus)

    Objective: To study the efficiency and SE of DBS in PD patients in Republican Research and Clinical Center of Neurology and Neurosurgery in Belarus for…
  • 2022 International Congress

    The Journey Of Levodopa Treatment in Parkinson’s disease

    B. Pandey (Tirupati, India)

    Objective: This study aims to relook the journey of levodopa in the treatment of Parkinson’s disease. Background: Levodopa has been used in the treatment of…
  • 2022 International Congress

    Levodopa-carbidopa intestinal gel (LCIG) as an add-on therapy to deep brain stimulation (DBS) for managing progressive symptoms of advanced idiopathic Parkinson’s disease during the COVID-19 pandemic: Case Report

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report the use of levodopa-carbidopa intestinal gel (LCIG) as an additional therapy for the treatment of motor fluctuations in a patient with advanced…
  • 2022 International Congress

    GLA-associated early-onset Parkinson’s disease: the mimicry between Fabry disease and parkinsonisms

    O. de Fabregues, A. Pascual-Rodríguez, M. de Lucca, M. Sellés, F. Palau, G. Fernández, J. Hoenicka (Barcelona, Spain)

    Objective: To characterize an early-onset Parkinson’s disease (EOPD) patient with atypical clinical phenotype. Background: Genome sequencing is allowing new Parkinsonian Syndromes (PS)-associated genes identification. However,…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley